Reich 2004

Methods	RCT, placebo‐controlled, double blind Date of study: not stated Setting: multicenter (locations not stated)
Participants	Randomised: 195 participants (no description of the study population) Inclusion criteria Participants with moderate‐severe psoriasis (BSA ≥ 10) Age ≥ 16 years Non‐response to phototherapy Non‐response to conventional systemic treatment Number of allowed previous treatments: 3 Exclusion criteria Previous treatments > 3 Dropouts and withdrawals Not stated
Interventions	Intervention A. Alefacept (n = 130), IM, 15 mg, once a week, 12 weeks Control Intervention B. Placebo (n = 65), IM, once a week, 12 weeks
Outcomes	Assessments at 14 weeks Primary or secondary outcomes of the trial PASI50 Outcomes of the trial AEs
Notes	Funding: not stated Abstracts: “Alefacept in the treatment of psoriasis for whom conventional therapies are ineffective or inappropriate” published in 2004 in the Journal of the European Academy of Dermatology and Venereology, Poster P105 We asked the study authors to provide the protocol and results by email. The had no acces to the data ("I do not have access to the data you require") Finally, as the 'Risk of bias' tool assessment was not possible and there were missing data for the results, Reich 2004 was included in "awaiting classification".